Eugene serves as Co-Head of Healthcare Investment Banking and U.S. Head of Biotechnology and Specialty Pharmaceuticals, focused on mergers and acquisitions and capital raising transactions. He joined us in 2010 to enhance our emerging therapeutics sector focus, bringing over 19 years of significant life sciences investment banking experience at HSBC, Wells Fargo, and Robertson Stephens. He has advised clients on a wide variety of corporate finance and strategic assignments, including mergers & acquisitions, IPOs, public offerings and private placements of debt and equity securities, PIPEs and LBOs for both public and private companies. Eugene graduated from the Leonard N. Stern School of Business at New York University with an MBA and a degree in Biology from New York University.
Selected Transactions
-
$258m
ATAI Life Sciences B.V.
Lead Manager (IPO)
-
BCTG Acquisition Corp.
N/a
BCTG Acquisition Corp.
Financial Advisor to BCTG Acquisition Corp. on its merger with Tango Therapeutics
-
US$175m
Travere Therapeutics Inc.
Lead Manager (Follow-on)
-
US$69m
Kaledio
Lead Manager (Follow-On)
-
US$173m
Rhythm Pharmaceuticals, Inc.
Lead Manager (Follow-On)
-
US$22m
Delcath Systems, Inc
Joint Bookrunner (Follow-On)
-
US$175m
Atara Biotherapeutics
Lead Manager (Follow-On Offering)
-
US$40m
Amryt Pharma Plc
Co-Agent (Private Placement)
-
US$145m
Sigilon Therapeutics
Bookrunner (IPO)